On Wednesday, leading independent equity research and corporate access firm SeeThruEquity announced that it has initiated coverage on Immune Therapeutics, Inc. (OTCQB: IMUN) with a 12-month price target of $0.61. IMUN is a specialty pharmaceutical company engaged in the manufacture, distribution and marketing of proprietary therapies targeting chronic, life-threatening diseases through the activation of the […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.